BR112016026518A2 - Ácidos hidroxâmicos heterocíclicos como inibidores da proteína desacetilase e inibidores duais de proteína desacetilase-proteína cinase e métodos de uso dos mesmos - Google Patents
Ácidos hidroxâmicos heterocíclicos como inibidores da proteína desacetilase e inibidores duais de proteína desacetilase-proteína cinase e métodos de uso dos mesmosInfo
- Publication number
- BR112016026518A2 BR112016026518A2 BR112016026518A BR112016026518A BR112016026518A2 BR 112016026518 A2 BR112016026518 A2 BR 112016026518A2 BR 112016026518 A BR112016026518 A BR 112016026518A BR 112016026518 A BR112016026518 A BR 112016026518A BR 112016026518 A2 BR112016026518 A2 BR 112016026518A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- inhibitors
- deacetylase
- hydroxamic acids
- methods
- Prior art date
Links
- 102000003964 Histone deacetylase Human genes 0.000 title abstract 5
- 108090000353 Histone deacetylase Proteins 0.000 title abstract 5
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title abstract 2
- 230000009977 dual effect Effects 0.000 title abstract 2
- 239000003909 protein kinase inhibitor Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102100036109 Dual specificity protein kinase TTK Human genes 0.000 abstract 2
- 101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461996691P | 2014-05-14 | 2014-05-14 | |
| US201461996702P | 2014-05-14 | 2014-05-14 | |
| PCT/US2015/030842 WO2015175813A1 (en) | 2014-05-14 | 2015-05-14 | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016026518A2 true BR112016026518A2 (pt) | 2017-08-15 |
Family
ID=54480695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016026518A BR112016026518A2 (pt) | 2014-05-14 | 2015-05-14 | Ácidos hidroxâmicos heterocíclicos como inibidores da proteína desacetilase e inibidores duais de proteína desacetilase-proteína cinase e métodos de uso dos mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9840520B2 (https=) |
| EP (1) | EP3142652B1 (https=) |
| JP (1) | JP6803235B2 (https=) |
| KR (1) | KR20170003688A (https=) |
| CN (1) | CN106456580B (https=) |
| BR (1) | BR112016026518A2 (https=) |
| CA (1) | CA2949163A1 (https=) |
| MX (1) | MX2016014911A (https=) |
| RU (1) | RU2016148863A (https=) |
| TW (1) | TW201625620A (https=) |
| WO (1) | WO2015175813A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016005199B1 (pt) | 2013-08-23 | 2022-02-22 | Neupharma, Inc | Certos compostos químicos, composições, e métodos |
| US9840520B2 (en) | 2014-05-14 | 2017-12-12 | The Regents Of The University Of Colorado, A Body Corporate | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof |
| WO2016095881A1 (en) * | 2014-12-15 | 2016-06-23 | Univerzita Palackeho V Olomouci | Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress |
| EP3270694A4 (en) * | 2015-02-17 | 2018-09-05 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CN106831780A (zh) * | 2015-12-03 | 2017-06-13 | 南开大学 | 具有cdk4/6和hdac抑制活性的新型杂环衍生物 |
| WO2018035061A1 (en) | 2016-08-15 | 2018-02-22 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| KR102477063B1 (ko) * | 2016-10-28 | 2022-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물 |
| IT201700041723A1 (it) * | 2017-04-14 | 2018-10-14 | Italfarmaco Spa | Nuovi inibitori selettivi di HDAC6 |
| CN107513064B (zh) * | 2017-09-27 | 2019-07-09 | 南昌大学 | 一种嘌呤异羟肟酸衍生物及其制备方法和应用 |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| KR102847312B1 (ko) * | 2021-12-30 | 2025-08-19 | 한국화학연구원 | 피라졸로피리미딘 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| EP4458827A4 (en) * | 2021-12-30 | 2025-10-29 | Korea Res Inst Chemical Tech | PYRAZOLOPYRIMIDINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION CONTAINING IT AS THE ACTIVE INGREDIENT |
| CN114685507B (zh) * | 2022-04-06 | 2024-01-12 | 山东大学 | 嘌呤胺衍生物类cdk2抑制剂及其制备方法和应用 |
| KR102792443B1 (ko) * | 2022-05-13 | 2025-04-08 | 서울대학교산학협력단 | Cdk를 저해하는 신규 피롤로피리미디논 카복사미드 화합물, 이의 입체이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암 치료용 약학적 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998039326A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
| US6638952B1 (en) * | 1997-03-04 | 2003-10-28 | Pharmacia Corporation | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
| NZ337326A (en) | 1997-03-04 | 2001-05-25 | Monsanto Co | Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds to inhibit the activity of matrix metalloproteinases |
| WO1999025687A1 (en) * | 1997-11-14 | 1999-05-27 | G.D. Searle & Co. | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| US20020049237A1 (en) | 1998-03-17 | 2002-04-25 | Newton Roger Schofield | Statin-MMP inhibitor combinations |
| AU2002246983A1 (en) * | 2001-01-11 | 2002-07-24 | Bristol-Myers Squibb Pharma Company | 1,2-disubstituted cyclic inhibitors of matrix metallorproteases and tnf-alpha |
| JPWO2002074298A1 (ja) * | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| PE20030701A1 (es) * | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| AU2003900608A0 (en) * | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
| BRPI0409227C1 (pt) * | 2003-04-07 | 2021-05-25 | Axys Pharm Inc | composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i) |
| CA2532403A1 (en) * | 2003-07-17 | 2005-02-03 | James Arnold | Ppar active compounds |
| DK1981871T3 (da) * | 2006-01-19 | 2012-02-13 | Janssen Pharmaceutica Nv | Heterocyclylalkylderivater som hidtil ukendte inhibitorer af histondeacetylase |
| WO2008053131A1 (en) | 2006-10-30 | 2008-05-08 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
| CA2673965A1 (en) | 2006-12-28 | 2008-07-10 | Taisho Pharmaceutical Co., Ltd. | Pyrazolopyrimidine compound |
| WO2009036066A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| WO2009036020A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Mek inhibitors containing a zinc binding moiety |
| KR101168801B1 (ko) * | 2009-03-27 | 2012-07-25 | 주식회사종근당 | 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물 |
| PH12012501492B1 (en) * | 2010-01-22 | 2020-01-24 | Acetylon Pharmaceuticals Inc | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
| US8513421B2 (en) * | 2010-05-19 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2012170827A2 (en) | 2011-06-08 | 2012-12-13 | Cylene Pharmaceuticals, Inc. | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
| WO2013041407A1 (en) | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
| KR20140118575A (ko) * | 2013-03-29 | 2014-10-08 | 한미약품 주식회사 | 신규한 하이드록사메이트 유도체 |
| US9840520B2 (en) | 2014-05-14 | 2017-12-12 | The Regents Of The University Of Colorado, A Body Corporate | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof |
-
2015
- 2015-05-14 US US15/310,743 patent/US9840520B2/en not_active Ceased
- 2015-05-14 CN CN201580024748.8A patent/CN106456580B/zh active Active
- 2015-05-14 EP EP15792349.1A patent/EP3142652B1/en active Active
- 2015-05-14 US US15/968,188 patent/USRE47690E1/en active Active
- 2015-05-14 WO PCT/US2015/030842 patent/WO2015175813A1/en not_active Ceased
- 2015-05-14 KR KR1020167035003A patent/KR20170003688A/ko not_active Withdrawn
- 2015-05-14 TW TW104115502A patent/TW201625620A/zh unknown
- 2015-05-14 MX MX2016014911A patent/MX2016014911A/es unknown
- 2015-05-14 BR BR112016026518A patent/BR112016026518A2/pt not_active IP Right Cessation
- 2015-05-14 CA CA2949163A patent/CA2949163A1/en not_active Abandoned
- 2015-05-14 RU RU2016148863A patent/RU2016148863A/ru unknown
- 2015-05-14 JP JP2016567524A patent/JP6803235B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-19 US US15/654,662 patent/US10508122B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170081343A1 (en) | 2017-03-23 |
| CN106456580B (zh) | 2020-09-04 |
| EP3142652A1 (en) | 2017-03-22 |
| CN106456580A (zh) | 2017-02-22 |
| TW201625620A (zh) | 2016-07-16 |
| WO2015175813A1 (en) | 2015-11-19 |
| RU2016148863A3 (https=) | 2018-12-17 |
| CA2949163A1 (en) | 2015-11-19 |
| EP3142652B1 (en) | 2021-08-25 |
| MX2016014911A (es) | 2017-04-06 |
| US20180044352A1 (en) | 2018-02-15 |
| USRE47690E1 (en) | 2019-11-05 |
| RU2016148863A (ru) | 2018-06-18 |
| US10508122B2 (en) | 2019-12-17 |
| JP2017515848A (ja) | 2017-06-15 |
| KR20170003688A (ko) | 2017-01-09 |
| EP3142652A4 (en) | 2017-11-29 |
| JP6803235B2 (ja) | 2020-12-23 |
| US9840520B2 (en) | 2017-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016026518A2 (pt) | Ácidos hidroxâmicos heterocíclicos como inibidores da proteína desacetilase e inibidores duais de proteína desacetilase-proteína cinase e métodos de uso dos mesmos | |
| BR112015027114A2 (pt) | novos compostos para os inibidores seletivos de histona desacetilase, e composição farmacêutica compreendendo os mesmos | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| EP3881846A4 (en) | PHARMACEUTICAL COMPOSITION WITH PARP INHIBITORS | |
| BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
| MX2020005841A (es) | Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6. | |
| BR112016017041A2 (pt) | Proteína isolada tendo atividade de fosfatase, polinucleotídeo, vetor, célula hospedeira, método para produzir uma proteína e composição | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| BR112017022604A2 (pt) | composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação | |
| BR112018071408A2 (pt) | “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação | |
| EA201500207A1 (ru) | Гетероароматические соединения в качестве ингибиторов втк | |
| EA201400986A1 (ru) | Фармацевтические композиции, содержащие метформин и ингибитор dpp-4 или ингибитор sglt-2 | |
| BR112016015838A8 (pt) | compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação | |
| BR112012028091A2 (pt) | composições farmacêuticas compreendendo pioglitazona e linagliptina | |
| BR112017023710A2 (pt) | inibidores de histona deacetilase e composições e métodos de uso dos mesmos | |
| BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| BR112019000589A2 (pt) | pirimidina carboxamidas como inibidores da enzima vanina-1 | |
| BR112017019653A2 (pt) | derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd | |
| BR112017003745A2 (pt) | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico | |
| MX384798B (es) | Piridinona dicarboxamida para uso como inhibidores de bromodominio. | |
| BR112017023225A2 (pt) | inibidor de proteína cinase | |
| BR112017008312A2 (pt) | novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2670 DE 08-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |